NO2829881T3 - - Google Patents

Info

Publication number
NO2829881T3
NO2829881T3 NO14178981A NO14178981A NO2829881T3 NO 2829881 T3 NO2829881 T3 NO 2829881T3 NO 14178981 A NO14178981 A NO 14178981A NO 14178981 A NO14178981 A NO 14178981A NO 2829881 T3 NO2829881 T3 NO 2829881T3
Authority
NO
Norway
Application number
NO14178981A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2010903140A external-priority patent/AU2010903140A0/en
Application filed filed Critical
Publication of NO2829881T3 publication Critical patent/NO2829881T3/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57419Specifically defined cancers of colon
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
NO14178981A 2010-07-14 2011-07-14 NO2829881T3 (cg-RX-API-DMAC7.html)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2010903140A AU2010903140A0 (en) 2010-07-14 Diagnostic for colorectal cancer
EP11806149.8A EP2593795A4 (en) 2010-07-14 2011-07-14 DIAGNOSIS FOR DARM CANCER

Publications (1)

Publication Number Publication Date
NO2829881T3 true NO2829881T3 (cg-RX-API-DMAC7.html) 2018-01-20

Family

ID=45468816

Family Applications (1)

Application Number Title Priority Date Filing Date
NO14178981A NO2829881T3 (cg-RX-API-DMAC7.html) 2010-07-14 2011-07-14

Country Status (13)

Country Link
US (2) US20130345322A1 (cg-RX-API-DMAC7.html)
EP (2) EP2829881B1 (cg-RX-API-DMAC7.html)
JP (1) JP6061344B2 (cg-RX-API-DMAC7.html)
CN (2) CN103140760B (cg-RX-API-DMAC7.html)
AU (1) AU2011279555B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013000745B1 (cg-RX-API-DMAC7.html)
DK (1) DK2829881T3 (cg-RX-API-DMAC7.html)
ES (1) ES2653646T3 (cg-RX-API-DMAC7.html)
IN (1) IN2013CN01129A (cg-RX-API-DMAC7.html)
NO (1) NO2829881T3 (cg-RX-API-DMAC7.html)
PT (1) PT2829881T (cg-RX-API-DMAC7.html)
RU (1) RU2013103995A (cg-RX-API-DMAC7.html)
WO (1) WO2012006681A1 (cg-RX-API-DMAC7.html)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130345322A1 (en) * 2010-07-14 2013-12-26 Commonwealth Scientific And Industrial Research Organisation Diagnostic for colorectal cancer
US9141756B1 (en) 2010-07-20 2015-09-22 University Of Southern California Multi-scale complex systems transdisciplinary analysis of response to therapy
CA2825894C (en) 2011-02-02 2021-11-30 Amgen Inc. Prognosis of cancer using a circulating biomarker
LT2883057T (lt) 2012-08-09 2019-04-25 Institut National De La Santé Et De La Recherche Médicale (Inserm) Širdies nepakankamumo diagnostika
GB201218341D0 (en) * 2012-10-12 2012-11-28 Orign Sciences Ltd Diagnostic method
CA2943827A1 (en) * 2014-03-28 2015-10-01 Applied Proteomics, Inc. Protein biomarker profiles for detecting colorectal tumors
WO2016008975A1 (en) * 2014-07-18 2016-01-21 Sanofi Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer
CN106191215B (zh) * 2015-04-29 2020-03-24 中国科学院上海生命科学研究院 肌肉萎缩相关的蛋白质分子标记Dkk-3的筛选及其应用
WO2016180335A1 (en) * 2015-05-12 2016-11-17 Superlab Far East Limited Methods of determining interferon having direct inhibitory effects on tumors and uses thereof
CN105219844B (zh) * 2015-06-08 2018-12-14 华夏京都医疗投资管理有限公司 一种筛查十一种疾病的基因标志物组合、试剂盒以及疾病风险预测模型
CN105021828B (zh) * 2015-07-20 2017-07-28 上海交通大学医学院附属新华医院 通过检测三期结直肠肿瘤患者血清预测肿瘤患者预后
CN105567846A (zh) * 2016-02-14 2016-05-11 上海交通大学医学院附属仁济医院 检测粪便中细菌dna的试剂盒及其在大肠癌诊断中的应用
JP6984862B2 (ja) * 2017-03-15 2021-12-22 国立大学法人金沢大学 血中ケモカインをマーカーとして用いた大腸癌の検出
CN107164535A (zh) * 2017-07-07 2017-09-15 沈阳宁沪科技有限公司 一种无创高通量甲基化结肠癌诊断、研究和治疗方法
CN110540588B (zh) * 2018-05-28 2022-08-23 香港中文大学 一种基于肿瘤干细胞标志物EpCAM的抗原表位多肽及其应用
CN108957014A (zh) * 2018-09-27 2018-12-07 郑州大学第附属医院 结直肠癌血清标志物、表达评估方法、试剂盒及应用
WO2020086729A1 (en) * 2018-10-23 2020-04-30 Blackthorn Therapeutics, Inc. Systems and methods for screening, diagnosing, and stratifying patients
CN109504778B (zh) * 2019-01-11 2021-11-09 复旦大学附属中山医院 一种基于表观修饰的5hmC多分子标志物及结直肠癌早期诊断模型
KR102769007B1 (ko) * 2019-03-01 2025-02-14 어드밴스드 마커 디스커버리 에스.엘. 대장암 및/또는 이의 전암 단계 진단을 위한 단백질 시그니처
JP7300660B2 (ja) * 2019-04-03 2023-06-30 京都府公立大学法人 大腸がんの検出方法
JP7032764B2 (ja) * 2019-04-03 2022-03-09 京都府公立大学法人 大腸がんの検出方法
GB201906199D0 (en) * 2019-05-02 2019-06-19 Belgian Volition Sprl Method for the detection of cancer
US20220378877A1 (en) * 2019-11-13 2022-12-01 University Of Virginia Patent Foundation Treatment of clostridium difficile infections
EP3835789A1 (en) 2019-12-13 2021-06-16 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Biomarker panel for diagnosing colorectal cancer
WO2022130597A1 (ja) * 2020-12-18 2022-06-23 国立大学法人東北大学 推定装置、推定方法、推定プログラム、生成装置、及び、推定システム
WO2022140116A1 (en) * 2020-12-21 2022-06-30 Freenome Holdings, Inc. Markers for the early detection of colon cell proliferative disorders
KR20240004546A (ko) * 2021-04-20 2024-01-11 비전 테크 바이오 피티와이 엘티디 결장직장암에 대한 바이오마커
EP4384830A4 (en) * 2021-08-11 2025-09-24 Vision Tech Bio Pty Ltd METHOD FOR DETECTING ADENOMA
WO2023128419A1 (ko) * 2021-12-31 2023-07-06 주식회사 이노제닉스 대장암 및 대장 용종 또는 진행 선종의 선별 방법 및 그 응용
WO2023128429A1 (ko) * 2021-12-31 2023-07-06 주식회사 이노제닉스 대장암 및 진행 선종의 선별 검사 방법 및 그 응용
CN114594259B (zh) * 2022-04-22 2022-09-13 北京易科拜德科技有限公司 一种新型的用于结直肠癌预后预测和诊断的模型及其应用
PL441319A1 (pl) * 2022-05-31 2023-12-04 Uniwersytet Medyczny Im. Piastów Śląskich We Wrocławiu Zestaw biomarkerów białkowych i sposób diagnostyki raka jelita grubego in vitro
CN116219007A (zh) * 2022-09-15 2023-06-06 绍兴积准生物科技有限公司 检测结直肠癌的生物标志物组及其应用
CN119688988A (zh) * 2024-11-25 2025-03-25 中国医学科学院肿瘤医院 Timp1和foxp3作为诊断结直肠癌的生物标志物组合及其应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925517A (en) 1993-11-12 1999-07-20 The Public Health Research Institute Of The City Of New York, Inc. Detectably labeled dual conformation oligonucleotide probes, assays and kits
JP2004198419A (ja) * 2002-12-13 2004-07-15 Bayer Healthcare Llc Timp1を用いた検出方法
US20050014165A1 (en) * 2003-07-18 2005-01-20 California Pacific Medical Center Biomarker panel for colorectal cancer
EP1664796B1 (en) * 2003-09-15 2010-12-15 Oklahoma Medical Research Foundation Method of using cytokine assays to diagnose, treat, and evaluate ankylosing spondylitis
BRPI0401830A (pt) 2004-05-25 2006-01-17 Bentonit Uniao Nordeste Sa Processo de produção de pós granulados secos
US20080112888A1 (en) * 2006-06-30 2008-05-15 Schering Corporation Igfbp2 biomarker
US9060961B2 (en) 2006-11-09 2015-06-23 University Of Washington Molecules and methods for treatment and detection of cancer
US9353415B2 (en) * 2006-12-19 2016-05-31 Thomson Reuters (Scientific) Llc Methods for functional analysis of high-throughput experimental data and gene groups identified therefrom
US20080221056A1 (en) 2007-02-12 2008-09-11 Johns Hopkins University Early Detection and Prognosis of Colon Cancers
DK2472264T3 (en) * 2007-02-27 2016-02-29 Sentoclone Internat Ab Multiplekspåvisning of tumor cells using a panel of agents which bind to extracellular markers
WO2008116178A2 (en) * 2007-03-21 2008-09-25 Vanderbilt University Systems and methods for diagnosis and prognosis of colorectal cancer
JP2010526995A (ja) * 2007-05-10 2010-08-05 エフ.ホフマン−ラ ロシュ アーゲー 結腸直腸癌のマーカーとしてのtimp−1の使用
US8492328B2 (en) * 2007-05-17 2013-07-23 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators
CA2688558A1 (en) * 2007-06-04 2009-03-26 Diagnoplex Biomarker combinations for colorectal cancer
US20090017463A1 (en) * 2007-07-10 2009-01-15 Vanderbilt University Methods for predicting prostate cancer recurrence
EP2271775A4 (en) * 2008-04-08 2011-09-07 Nuclea Biomarkers Llc BIOMARKERGROUP FOR PREDICTING THE REPRESENTATION OF COLORECTAL CARCINOMA
US20100111969A1 (en) * 2008-10-31 2010-05-06 Apogenix Gmbh Il-4 receptor and il-13 as prognostic markers for colon and pancreas tumors
AU2009322474A1 (en) * 2008-12-01 2011-07-21 Lifespan Extension Llc Methods and compositions for altering health, wellbeing, and lifespan
US20110236903A1 (en) * 2008-12-04 2011-09-29 Mcclelland Michael Materials and methods for determining diagnosis and prognosis of prostate cancer
WO2010096674A2 (en) * 2009-02-20 2010-08-26 The Regents Of The University Of California A+ biomarker assays
US20110177525A1 (en) * 2010-01-19 2011-07-21 Predictive Biosciences, Inc. Antibodies and methods of diagnosing diseases
US20130345322A1 (en) * 2010-07-14 2013-12-26 Commonwealth Scientific And Industrial Research Organisation Diagnostic for colorectal cancer

Also Published As

Publication number Publication date
EP2829881A2 (en) 2015-01-28
CN103140760A (zh) 2013-06-05
AU2011279555B2 (en) 2016-10-20
AU2011279555A1 (en) 2013-01-31
EP2593795A1 (en) 2013-05-22
ES2653646T3 (es) 2018-02-08
CN105755112A (zh) 2016-07-13
DK2829881T3 (en) 2017-12-04
WO2012006681A1 (en) 2012-01-19
US10877039B2 (en) 2020-12-29
US20130345322A1 (en) 2013-12-26
IN2013CN01129A (cg-RX-API-DMAC7.html) 2015-07-31
EP2593795A4 (en) 2014-01-22
JP6061344B2 (ja) 2017-01-18
CN103140760B (zh) 2016-01-27
BR112013000745A2 (pt) 2016-05-24
US20170205414A1 (en) 2017-07-20
EP2829881A3 (en) 2015-05-13
JP2013533977A (ja) 2013-08-29
CN105755112B (zh) 2019-06-07
EP2829881B1 (en) 2017-08-23
RU2013103995A (ru) 2014-08-20
PT2829881T (pt) 2017-11-29
BR112013000745B1 (pt) 2021-02-02

Similar Documents

Publication Publication Date Title
BR112013008959A2 (cg-RX-API-DMAC7.html)
BR112012030039A2 (cg-RX-API-DMAC7.html)
BR112012028408A2 (cg-RX-API-DMAC7.html)
BR112012029986A2 (cg-RX-API-DMAC7.html)
BR112012027808A2 (cg-RX-API-DMAC7.html)
BR112012024897A2 (cg-RX-API-DMAC7.html)
BR112012026492A2 (cg-RX-API-DMAC7.html)
BR112012031500A2 (cg-RX-API-DMAC7.html)
BR112012025307A2 (cg-RX-API-DMAC7.html)
BR112012026946A2 (cg-RX-API-DMAC7.html)
BR112012025482A2 (cg-RX-API-DMAC7.html)
BR112013006400A2 (cg-RX-API-DMAC7.html)
BR112012031826A2 (cg-RX-API-DMAC7.html)
NO2829881T3 (cg-RX-API-DMAC7.html)
BR112012025577A2 (cg-RX-API-DMAC7.html)
BR112012028186A2 (cg-RX-API-DMAC7.html)
BR112012027015A2 (cg-RX-API-DMAC7.html)
BR112012025308A2 (cg-RX-API-DMAC7.html)
BR112012027945A2 (cg-RX-API-DMAC7.html)
BR112013010949A2 (cg-RX-API-DMAC7.html)
BR112012024872A2 (cg-RX-API-DMAC7.html)
BR112013003284A2 (cg-RX-API-DMAC7.html)
BR112012026403A2 (cg-RX-API-DMAC7.html)
BR112013002646A2 (cg-RX-API-DMAC7.html)
BR112013006825A2 (cg-RX-API-DMAC7.html)